ABPI welcomes launch of £80M New Treatment Fund for Wales

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the Welsh Government’s launch of a £80 million New Treatment Fund aimed at speeding up access to the very latest medicines for Welsh NHS patients, 

The ABPI advocated for the new funding mechanism in the build-up to the 2016 National Assembly for Wales elections as a way of delivering ‘equitable and consistent patient access to the latest medicines, no matter the disease area”. Annually, it will provide additional support of £16 million to Welsh health boards until 2021.

Under the new system, confirmed today by Health Secretary Vaughan Gething, AM, all health boards in Wales will be required to make a National Institute for Health and Care Excellence or All Wales Medicines Strategy Group recommended medicine available no later than two months from the date that guidance is published. 

Dr Rick Greville, ABPI Director with responsibility for Wales, said: “Today’s announcement is great news for NHS patients in Wales and is the type of progressive policy which can make a real impact on patients’ lives. From today, the people of Wales should look forward to the prospect of benefitting from the right medicines, for all patients, at the earliest time.”